nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—CYP3A4—bone cancer	0.508	1	CbGaD
Fluoxetine—CYP2B6—Cisplatin—bone cancer	0.0399	0.22	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—bone cancer	0.0267	0.147	CbGbCtD
Fluoxetine—ALB—Methotrexate—bone cancer	0.0254	0.14	CbGbCtD
Fluoxetine—CYP2C9—Cisplatin—bone cancer	0.0211	0.116	CbGbCtD
Fluoxetine—ABCB1—Cisplatin—bone cancer	0.0205	0.113	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—bone cancer	0.0137	0.0755	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—bone cancer	0.0133	0.0731	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—bone cancer	0.0129	0.0711	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—bone cancer	0.00822	0.0452	CbGbCtD
Fluoxetine—Cinacalcet—CYP3A4—bone cancer	0.000631	0.58	CrCbGaD
Fluoxetine—Atomoxetine—CYP3A4—bone cancer	0.000259	0.238	CrCbGaD
Fluoxetine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000231	0.00479	CbGpPWpGaD
Fluoxetine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000228	0.00473	CbGpPWpGaD
Fluoxetine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000226	0.00469	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000226	0.00468	CbGpPWpGaD
Fluoxetine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000223	0.00462	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—GRM1—bone cancer	0.000215	0.00446	CbGpPWpGaD
Fluoxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000215	0.00445	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—DHFR—bone cancer	0.000213	0.00441	CbGpPWpGaD
Fluoxetine—Orphenadrine—CYP3A4—bone cancer	0.000198	0.182	CrCbGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000193	0.00399	CbGpPWpGaD
Fluoxetine—Renal failure—Epirubicin—bone cancer	0.00019	0.000729	CcSEcCtD
Fluoxetine—Body temperature increased—Cisplatin—bone cancer	0.00019	0.000728	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Epirubicin—bone cancer	0.00019	0.000727	CcSEcCtD
Fluoxetine—SLC6A4—NRF2 pathway—GSTP1—bone cancer	0.000189	0.00392	CbGpPWpGaD
Fluoxetine—SLC6A4—NRF2 pathway—TGFBR2—bone cancer	0.000189	0.00392	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—GNA11—bone cancer	0.000189	0.00392	CbGpPWpGaD
Fluoxetine—Stomatitis—Epirubicin—bone cancer	0.000189	0.000723	CcSEcCtD
Fluoxetine—Jaundice—Epirubicin—bone cancer	0.000189	0.000723	CcSEcCtD
Fluoxetine—Conjunctivitis—Epirubicin—bone cancer	0.000188	0.000721	CcSEcCtD
Fluoxetine—Urinary tract infection—Epirubicin—bone cancer	0.000188	0.000721	CcSEcCtD
Fluoxetine—SLC6A4—Circadian rythm related genes—EZH2—bone cancer	0.000188	0.0039	CbGpPWpGaD
Fluoxetine—Dysuria—Doxorubicin—bone cancer	0.000188	0.00072	CcSEcCtD
Fluoxetine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000188	0.00389	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—GRM1—bone cancer	0.000187	0.00388	CbGpPWpGaD
Fluoxetine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000187	0.000716	CcSEcCtD
Fluoxetine—Haemoglobin—Methotrexate—bone cancer	0.000187	0.000715	CcSEcCtD
Fluoxetine—ALB—Platelet degranulation—SPARC—bone cancer	0.000187	0.00387	CbGpPWpGaD
Fluoxetine—Haemorrhage—Methotrexate—bone cancer	0.000186	0.000712	CcSEcCtD
Fluoxetine—Hepatitis—Methotrexate—bone cancer	0.000186	0.000712	CcSEcCtD
Fluoxetine—Sweating—Epirubicin—bone cancer	0.000186	0.000711	CcSEcCtD
Fluoxetine—Pollakiuria—Doxorubicin—bone cancer	0.000186	0.000711	CcSEcCtD
Fluoxetine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000185	0.00383	CbGpPWpGaD
Fluoxetine—Haematuria—Epirubicin—bone cancer	0.000185	0.000707	CcSEcCtD
Fluoxetine—Pharyngitis—Methotrexate—bone cancer	0.000184	0.000706	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Doxorubicin—bone cancer	0.000183	0.000703	CcSEcCtD
Fluoxetine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000183	0.0038	CbGpPWpGaD
Fluoxetine—Weight increased—Doxorubicin—bone cancer	0.000183	0.000701	CcSEcCtD
Fluoxetine—Epistaxis—Epirubicin—bone cancer	0.000183	0.0007	CcSEcCtD
Fluoxetine—Weight decreased—Doxorubicin—bone cancer	0.000182	0.000697	CcSEcCtD
Fluoxetine—Sinusitis—Epirubicin—bone cancer	0.000182	0.000696	CcSEcCtD
Fluoxetine—Hyperglycaemia—Doxorubicin—bone cancer	0.000181	0.000695	CcSEcCtD
Fluoxetine—Pneumonia—Doxorubicin—bone cancer	0.00018	0.000691	CcSEcCtD
Fluoxetine—Drowsiness—Doxorubicin—bone cancer	0.000179	0.000687	CcSEcCtD
Fluoxetine—Visual impairment—Methotrexate—bone cancer	0.000179	0.000686	CcSEcCtD
Fluoxetine—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000178	0.00368	CbGpPWpGaD
Fluoxetine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000178	0.000681	CcSEcCtD
Fluoxetine—Hypersensitivity—Cisplatin—bone cancer	0.000177	0.000679	CcSEcCtD
Fluoxetine—Bradycardia—Epirubicin—bone cancer	0.000177	0.000678	CcSEcCtD
Fluoxetine—Renal failure—Doxorubicin—bone cancer	0.000176	0.000675	CcSEcCtD
Fluoxetine—Erythema multiforme—Methotrexate—bone cancer	0.000176	0.000673	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000176	0.000673	CcSEcCtD
Fluoxetine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000175	0.00362	CbGpPWpGaD
Fluoxetine—Haemoglobin—Epirubicin—bone cancer	0.000175	0.000669	CcSEcCtD
Fluoxetine—Stomatitis—Doxorubicin—bone cancer	0.000175	0.000669	CcSEcCtD
Fluoxetine—Jaundice—Doxorubicin—bone cancer	0.000175	0.000669	CcSEcCtD
Fluoxetine—Rhinitis—Epirubicin—bone cancer	0.000174	0.000668	CcSEcCtD
Fluoxetine—Conjunctivitis—Doxorubicin—bone cancer	0.000174	0.000667	CcSEcCtD
Fluoxetine—Urinary tract infection—Doxorubicin—bone cancer	0.000174	0.000667	CcSEcCtD
Fluoxetine—Haemorrhage—Epirubicin—bone cancer	0.000174	0.000666	CcSEcCtD
Fluoxetine—Hepatitis—Epirubicin—bone cancer	0.000174	0.000666	CcSEcCtD
Fluoxetine—Tinnitus—Methotrexate—bone cancer	0.000173	0.000664	CcSEcCtD
Fluoxetine—Hypoaesthesia—Epirubicin—bone cancer	0.000173	0.000663	CcSEcCtD
Fluoxetine—Asthenia—Cisplatin—bone cancer	0.000173	0.000661	CcSEcCtD
Fluoxetine—Pharyngitis—Epirubicin—bone cancer	0.000173	0.000661	CcSEcCtD
Fluoxetine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000173	0.00358	CbGpPWpGaD
Fluoxetine—Sweating—Doxorubicin—bone cancer	0.000172	0.000658	CcSEcCtD
Fluoxetine—Oedema peripheral—Epirubicin—bone cancer	0.000171	0.000656	CcSEcCtD
Fluoxetine—Haematuria—Doxorubicin—bone cancer	0.000171	0.000655	CcSEcCtD
Fluoxetine—Epistaxis—Doxorubicin—bone cancer	0.000169	0.000648	CcSEcCtD
Fluoxetine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000169	0.00349	CbGpPWpGaD
Fluoxetine—Sinusitis—Doxorubicin—bone cancer	0.000168	0.000644	CcSEcCtD
Fluoxetine—Visual impairment—Epirubicin—bone cancer	0.000168	0.000642	CcSEcCtD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000167	0.00347	CbGpPWpGaD
Fluoxetine—Chills—Methotrexate—bone cancer	0.000167	0.000639	CcSEcCtD
Fluoxetine—Diarrhoea—Cisplatin—bone cancer	0.000165	0.00063	CcSEcCtD
Fluoxetine—Erythema multiforme—Epirubicin—bone cancer	0.000164	0.00063	CcSEcCtD
Fluoxetine—Alopecia—Methotrexate—bone cancer	0.000164	0.000629	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—bone cancer	0.000164	0.000627	CcSEcCtD
Fluoxetine—Mental disorder—Methotrexate—bone cancer	0.000163	0.000624	CcSEcCtD
Fluoxetine—SLC6A2—NRF2 pathway—TGFBR2—bone cancer	0.000163	0.00337	CbGpPWpGaD
Fluoxetine—SLC6A2—NRF2 pathway—GSTP1—bone cancer	0.000163	0.00337	CbGpPWpGaD
Fluoxetine—Tinnitus—Epirubicin—bone cancer	0.000162	0.000621	CcSEcCtD
Fluoxetine—Malnutrition—Methotrexate—bone cancer	0.000162	0.00062	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—bone cancer	0.000162	0.000619	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—bone cancer	0.000161	0.000618	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—bone cancer	0.000161	0.000616	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—bone cancer	0.000161	0.000616	CcSEcCtD
Fluoxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000161	0.00333	CbGpPWpGaD
Fluoxetine—Hypoaesthesia—Doxorubicin—bone cancer	0.00016	0.000613	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—bone cancer	0.00016	0.000612	CcSEcCtD
Fluoxetine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000159	0.0033	CbGpPWpGaD
Fluoxetine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000159	0.00329	CbGpPWpGaD
Fluoxetine—Oedema peripheral—Doxorubicin—bone cancer	0.000159	0.000607	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—bone cancer	0.000158	0.000607	CcSEcCtD
Fluoxetine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000157	0.00326	CbGpPWpGaD
Fluoxetine—Back pain—Methotrexate—bone cancer	0.000156	0.000599	CcSEcCtD
Fluoxetine—Chills—Epirubicin—bone cancer	0.000156	0.000598	CcSEcCtD
Fluoxetine—Arrhythmia—Epirubicin—bone cancer	0.000155	0.000595	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—bone cancer	0.000155	0.000594	CcSEcCtD
Fluoxetine—Alopecia—Epirubicin—bone cancer	0.000154	0.000589	CcSEcCtD
Fluoxetine—Vomiting—Cisplatin—bone cancer	0.000153	0.000586	CcSEcCtD
Fluoxetine—Mental disorder—Epirubicin—bone cancer	0.000152	0.000584	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—bone cancer	0.000152	0.000583	CcSEcCtD
Fluoxetine—Rash—Cisplatin—bone cancer	0.000152	0.000581	CcSEcCtD
Fluoxetine—Dermatitis—Cisplatin—bone cancer	0.000152	0.00058	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—bone cancer	0.000151	0.00058	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—bone cancer	0.00015	0.000575	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—bone cancer	0.00015	0.000575	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—bone cancer	0.00015	0.000573	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—bone cancer	0.000149	0.000571	CcSEcCtD
Fluoxetine—Tension—Epirubicin—bone cancer	0.000149	0.000569	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—bone cancer	0.000148	0.000568	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—bone cancer	0.000147	0.000563	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—bone cancer	0.000146	0.000561	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—bone cancer	0.000146	0.000559	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—bone cancer	0.000146	0.000557	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—bone cancer	0.000145	0.000557	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—bone cancer	0.000145	0.000555	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—bone cancer	0.000144	0.000553	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—bone cancer	0.000144	0.000551	CcSEcCtD
Fluoxetine—Nausea—Cisplatin—bone cancer	0.000143	0.000547	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—bone cancer	0.000142	0.000545	CcSEcCtD
Fluoxetine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000142	0.00294	CbGpPWpGaD
Fluoxetine—Cough—Methotrexate—bone cancer	0.000141	0.000541	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—bone cancer	0.000141	0.00054	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—bone cancer	0.00014	0.000538	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—bone cancer	0.00014	0.000537	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—bone cancer	0.00014	0.000536	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—bone cancer	0.00014	0.000536	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—bone cancer	0.000139	0.000533	CcSEcCtD
Fluoxetine—HTR2C—G alpha (q) signalling events—GNA11—bone cancer	0.000139	0.00288	CbGpPWpGaD
Fluoxetine—Flatulence—Doxorubicin—bone cancer	0.000138	0.000529	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—bone cancer	0.000138	0.000527	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—bone cancer	0.000138	0.000527	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—bone cancer	0.000138	0.000527	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—bone cancer	0.000137	0.000526	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—bone cancer	0.000137	0.000525	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000137	0.000524	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—bone cancer	0.000137	0.000523	CcSEcCtD
Fluoxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000136	0.00282	CbGpPWpGaD
Fluoxetine—Discomfort—Methotrexate—bone cancer	0.000136	0.000521	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—bone cancer	0.000136	0.000521	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—bone cancer	0.000136	0.000521	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—bone cancer	0.000136	0.00052	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—bone cancer	0.000136	0.000519	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—bone cancer	0.000135	0.000519	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—bone cancer	0.000135	0.000516	CcSEcCtD
Fluoxetine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000134	0.00279	CbGpPWpGaD
Fluoxetine—Palpitations—Epirubicin—bone cancer	0.000134	0.000512	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—bone cancer	0.000133	0.00051	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—bone cancer	0.000133	0.00051	CcSEcCtD
Fluoxetine—Cough—Epirubicin—bone cancer	0.000132	0.000506	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—bone cancer	0.000132	0.000506	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—bone cancer	0.000131	0.000502	CcSEcCtD
Fluoxetine—Infection—Methotrexate—bone cancer	0.000131	0.000502	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—bone cancer	0.000131	0.000501	CcSEcCtD
Fluoxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00013	0.0027	CbGpPWpGaD
Fluoxetine—Ill-defined disorder—Doxorubicin—bone cancer	0.00013	0.000498	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—bone cancer	0.000129	0.000496	CcSEcCtD
Fluoxetine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000129	0.00268	CbGpPWpGaD
Fluoxetine—Thrombocytopenia—Methotrexate—bone cancer	0.000129	0.000495	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—bone cancer	0.000129	0.000494	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—bone cancer	0.000129	0.000494	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—bone cancer	0.000129	0.000494	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—bone cancer	0.000129	0.000493	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—bone cancer	0.000128	0.000492	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—bone cancer	0.000128	0.000491	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000128	0.00049	CcSEcCtD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000128	0.00265	CbGpPWpGaD
Fluoxetine—Hyperhidrosis—Methotrexate—bone cancer	0.000128	0.000489	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—bone cancer	0.000127	0.000488	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—bone cancer	0.000126	0.000484	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—bone cancer	0.000126	0.000483	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—bone cancer	0.000126	0.000482	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—bone cancer	0.000126	0.000482	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—bone cancer	0.000126	0.000481	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—bone cancer	0.000125	0.00048	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—GRM4—bone cancer	0.000125	0.0026	CbGpPWpGaD
Fluoxetine—Confusional state—Epirubicin—bone cancer	0.000125	0.000477	CcSEcCtD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000124	0.00257	CbGpPWpGaD
Fluoxetine—Palpitations—Doxorubicin—bone cancer	0.000124	0.000474	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—bone cancer	0.000124	0.000473	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—bone cancer	0.000123	0.000473	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—bone cancer	0.000123	0.000472	CcSEcCtD
Fluoxetine—Infection—Epirubicin—bone cancer	0.000123	0.00047	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—bone cancer	0.000122	0.000468	CcSEcCtD
Fluoxetine—Shock—Epirubicin—bone cancer	0.000122	0.000466	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—bone cancer	0.000121	0.000465	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—bone cancer	0.000121	0.000463	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—bone cancer	0.000121	0.000463	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—bone cancer	0.000121	0.000462	CcSEcCtD
Fluoxetine—HTR2A—G alpha (q) signalling events—GNA11—bone cancer	0.000121	0.0025	CbGpPWpGaD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00012	0.000461	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—bone cancer	0.00012	0.00046	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—bone cancer	0.000119	0.000457	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—bone cancer	0.000119	0.000457	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—bone cancer	0.000119	0.000457	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—bone cancer	0.000119	0.000457	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—bone cancer	0.000119	0.000457	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—bone cancer	0.000119	0.000455	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—bone cancer	0.000119	0.000454	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000118	0.000454	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—bone cancer	0.000118	0.000451	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—bone cancer	0.000118	0.000451	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—bone cancer	0.000118	0.000451	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—bone cancer	0.000117	0.00045	CcSEcCtD
Fluoxetine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000117	0.00243	CbGpPWpGaD
Fluoxetine—Dry mouth—Doxorubicin—bone cancer	0.000117	0.000447	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—bone cancer	0.000116	0.000445	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—bone cancer	0.000115	0.000442	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—bone cancer	0.000115	0.000441	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—bone cancer	0.000115	0.00044	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—bone cancer	0.000114	0.000438	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000114	0.000437	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—bone cancer	0.000114	0.000436	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—bone cancer	0.000114	0.000435	CcSEcCtD
Fluoxetine—Pain—Methotrexate—bone cancer	0.000113	0.000432	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000113	0.000431	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—bone cancer	0.000112	0.000431	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—bone cancer	0.000112	0.000429	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—bone cancer	0.000112	0.000428	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—bone cancer	0.000112	0.000427	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—bone cancer	0.000111	0.000425	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—bone cancer	0.000111	0.000425	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—bone cancer	0.000111	0.000423	CcSEcCtD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00011	0.00229	CbGpPWpGaD
Fluoxetine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00011	0.00229	CbGpPWpGaD
Fluoxetine—Dyspnoea—Epirubicin—bone cancer	0.00011	0.000422	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—bone cancer	0.00011	0.000421	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—bone cancer	0.000109	0.000417	CcSEcCtD
Fluoxetine—HTR2A—GPCR ligand binding—GRM4—bone cancer	0.000109	0.00225	CbGpPWpGaD
Fluoxetine—Feeling abnormal—Methotrexate—bone cancer	0.000109	0.000417	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—bone cancer	0.000109	0.000417	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—GRM1—bone cancer	0.000109	0.00225	CbGpPWpGaD
Fluoxetine—Gastrointestinal pain—Methotrexate—bone cancer	0.000108	0.000413	CcSEcCtD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000108	0.00223	CbGpPWpGaD
Fluoxetine—Decreased appetite—Epirubicin—bone cancer	0.000107	0.000411	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—bone cancer	0.000107	0.000409	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000107	0.000409	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—bone cancer	0.000107	0.000408	CcSEcCtD
Fluoxetine—SLC6A4—Circadian rythm related genes—CDK4—bone cancer	0.000106	0.0022	CbGpPWpGaD
Fluoxetine—Pain—Epirubicin—bone cancer	0.000106	0.000405	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—bone cancer	0.000106	0.000405	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—bone cancer	0.000105	0.000402	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—bone cancer	0.000104	0.0004	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—bone cancer	0.000104	0.0004	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000104	0.000399	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—bone cancer	0.000103	0.000396	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—bone cancer	0.000103	0.000393	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—bone cancer	0.000102	0.00039	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—bone cancer	0.000102	0.00039	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—bone cancer	0.000102	0.000389	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—bone cancer	0.000101	0.000387	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—bone cancer	0.000101	0.000385	CcSEcCtD
Fluoxetine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	9.97e-05	0.00206	CbGpPWpGaD
Fluoxetine—Decreased appetite—Doxorubicin—bone cancer	9.94e-05	0.000381	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—bone cancer	9.87e-05	0.000378	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—bone cancer	9.86e-05	0.000377	CcSEcCtD
Fluoxetine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	9.83e-05	0.00204	CbGpPWpGaD
Fluoxetine—Urticaria—Epirubicin—bone cancer	9.81e-05	0.000376	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—bone cancer	9.78e-05	0.000374	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—bone cancer	9.78e-05	0.000374	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—bone cancer	9.77e-05	0.000374	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—bone cancer	9.77e-05	0.000374	CcSEcCtD
Fluoxetine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	9.74e-05	0.00202	CbGpPWpGaD
Fluoxetine—Hypersensitivity—Methotrexate—bone cancer	9.73e-05	0.000373	CcSEcCtD
Fluoxetine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	9.61e-05	0.00199	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	9.59e-05	0.00199	CbGpPWpGaD
Fluoxetine—Asthenia—Methotrexate—bone cancer	9.47e-05	0.000363	CcSEcCtD
Fluoxetine—HTR2A—GPCR ligand binding—GRM1—bone cancer	9.43e-05	0.00195	CbGpPWpGaD
Fluoxetine—Feeling abnormal—Doxorubicin—bone cancer	9.42e-05	0.000361	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—bone cancer	9.35e-05	0.000358	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—bone cancer	9.34e-05	0.000358	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—bone cancer	9.1e-05	0.000349	CcSEcCtD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	9.09e-05	0.00188	CbGpPWpGaD
Fluoxetine—Urticaria—Doxorubicin—bone cancer	9.08e-05	0.000348	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—bone cancer	9.04e-05	0.000346	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—bone cancer	9.04e-05	0.000346	CcSEcCtD
Fluoxetine—Diarrhoea—Methotrexate—bone cancer	9.03e-05	0.000346	CcSEcCtD
Fluoxetine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	8.97e-05	0.00186	CbGpPWpGaD
Fluoxetine—Asthenia—Epirubicin—bone cancer	8.86e-05	0.00034	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—bone cancer	8.74e-05	0.000335	CcSEcCtD
Fluoxetine—Dizziness—Methotrexate—bone cancer	8.73e-05	0.000334	CcSEcCtD
Fluoxetine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	8.58e-05	0.00178	CbGpPWpGaD
Fluoxetine—CYP2B6—Biological oxidations—GSTP1—bone cancer	8.52e-05	0.00177	CbGpPWpGaD
Fluoxetine—Diarrhoea—Epirubicin—bone cancer	8.45e-05	0.000324	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—bone cancer	8.42e-05	0.000323	CcSEcCtD
Fluoxetine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	8.41e-05	0.00174	CbGpPWpGaD
Fluoxetine—Vomiting—Methotrexate—bone cancer	8.39e-05	0.000322	CcSEcCtD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—JUN—bone cancer	8.38e-05	0.00174	CbGpPWpGaD
Fluoxetine—CYP3A5—Biological oxidations—GSTP1—bone cancer	8.33e-05	0.00173	CbGpPWpGaD
Fluoxetine—Rash—Methotrexate—bone cancer	8.32e-05	0.000319	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—bone cancer	8.32e-05	0.000319	CcSEcCtD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	8.28e-05	0.00172	CbGpPWpGaD
Fluoxetine—Headache—Methotrexate—bone cancer	8.27e-05	0.000317	CcSEcCtD
Fluoxetine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	8.22e-05	0.0017	CbGpPWpGaD
Fluoxetine—Asthenia—Doxorubicin—bone cancer	8.2e-05	0.000314	CcSEcCtD
Fluoxetine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.17e-05	0.00169	CbGpPWpGaD
Fluoxetine—Dizziness—Epirubicin—bone cancer	8.17e-05	0.000313	CcSEcCtD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	8.15e-05	0.00169	CbGpPWpGaD
Fluoxetine—Pruritus—Doxorubicin—bone cancer	8.09e-05	0.00031	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—bone cancer	7.86e-05	0.000301	CcSEcCtD
Fluoxetine—Nausea—Methotrexate—bone cancer	7.84e-05	0.0003	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—bone cancer	7.82e-05	0.0003	CcSEcCtD
Fluoxetine—Rash—Epirubicin—bone cancer	7.79e-05	0.000298	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—bone cancer	7.78e-05	0.000298	CcSEcCtD
Fluoxetine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	7.75e-05	0.0016	CbGpPWpGaD
Fluoxetine—Headache—Epirubicin—bone cancer	7.74e-05	0.000296	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—SMO—bone cancer	7.65e-05	0.00159	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	7.57e-05	0.00157	CbGpPWpGaD
Fluoxetine—Dizziness—Doxorubicin—bone cancer	7.56e-05	0.00029	CcSEcCtD
Fluoxetine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	7.53e-05	0.00156	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	7.47e-05	0.00155	CbGpPWpGaD
Fluoxetine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	7.43e-05	0.00154	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.42e-05	0.00154	CbGpPWpGaD
Fluoxetine—Nausea—Epirubicin—bone cancer	7.34e-05	0.000281	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—bone cancer	7.27e-05	0.000278	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—bone cancer	7.21e-05	0.000276	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—bone cancer	7.2e-05	0.000276	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—bone cancer	7.16e-05	0.000274	CcSEcCtD
Fluoxetine—HTR2C—GPCR downstream signaling—GRM4—bone cancer	7.08e-05	0.00147	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—RGS1—bone cancer	7.08e-05	0.00147	CbGpPWpGaD
Fluoxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.99e-05	0.00145	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.93e-05	0.00143	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	6.87e-05	0.00142	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	6.86e-05	0.00142	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—JUN—bone cancer	6.85e-05	0.00142	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.83e-05	0.00142	CbGpPWpGaD
Fluoxetine—Nausea—Doxorubicin—bone cancer	6.79e-05	0.00026	CcSEcCtD
Fluoxetine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	6.77e-05	0.0014	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6.76e-05	0.0014	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	6.73e-05	0.00139	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	6.67e-05	0.00138	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—SMO—bone cancer	6.65e-05	0.00138	CbGpPWpGaD
Fluoxetine—CYP2C19—Biological oxidations—GSTP1—bone cancer	6.44e-05	0.00133	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.43e-05	0.00133	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—GRM4—bone cancer	6.43e-05	0.00133	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—RGS1—bone cancer	6.43e-05	0.00133	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	6.35e-05	0.00132	CbGpPWpGaD
Fluoxetine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	6.35e-05	0.00132	CbGpPWpGaD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	6.32e-05	0.00131	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—GRM4—bone cancer	6.15e-05	0.00127	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—RGS1—bone cancer	6.15e-05	0.00127	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—GRM1—bone cancer	6.14e-05	0.00127	CbGpPWpGaD
Fluoxetine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.98e-05	0.00124	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NDUFA12—bone cancer	5.97e-05	0.00124	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.92e-05	0.00123	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.87e-05	0.00122	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.87e-05	0.00122	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.84e-05	0.00121	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NDUFA12—bone cancer	5.84e-05	0.00121	CbGpPWpGaD
Fluoxetine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.79e-05	0.0012	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	5.79e-05	0.0012	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.65e-05	0.00117	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.64e-05	0.00117	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—RGS1—bone cancer	5.58e-05	0.00116	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—GRM4—bone cancer	5.58e-05	0.00116	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—GRM1—bone cancer	5.57e-05	0.00115	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.55e-05	0.00115	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—GRM1—bone cancer	5.33e-05	0.0011	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	5.29e-05	0.0011	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.29e-05	0.0011	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—JUN—bone cancer	5.05e-05	0.00105	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NDUFA12—bone cancer	5.03e-05	0.00104	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.02e-05	0.00104	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NT5C3A—bone cancer	4.95e-05	0.00103	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.95e-05	0.00103	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.86e-05	0.00101	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—GRM1—bone cancer	4.84e-05	0.001	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NT5C3A—bone cancer	4.84e-05	0.001	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—TP53—bone cancer	4.76e-05	0.000986	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—TP53—bone cancer	4.52e-05	0.000936	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NDUFA12—bone cancer	4.51e-05	0.000935	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NDUFA12—bone cancer	4.41e-05	0.000913	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—SPARC—bone cancer	4.27e-05	0.000884	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.19e-05	0.000868	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NT5C3A—bone cancer	4.17e-05	0.000863	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NDUFA12—bone cancer	4.15e-05	0.00086	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NDUFA12—bone cancer	4.12e-05	0.000853	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—GNA11—bone cancer	3.96e-05	0.00082	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—SMO—bone cancer	3.93e-05	0.000814	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—GNA11—bone cancer	3.9e-05	0.000809	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.87e-05	0.000802	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.82e-05	0.000791	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RGS1—bone cancer	3.8e-05	0.000787	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GRM4—bone cancer	3.8e-05	0.000787	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NT5C3A—bone cancer	3.74e-05	0.000775	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NT5C3A—bone cancer	3.65e-05	0.000756	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—GNA11—bone cancer	3.59e-05	0.000744	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—IL3—bone cancer	3.59e-05	0.000743	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IL3—bone cancer	3.54e-05	0.000733	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.54e-05	0.000732	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NDUFA12—bone cancer	3.52e-05	0.000729	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NT5C3A—bone cancer	3.44e-05	0.000713	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—GNA11—bone cancer	3.44e-05	0.000712	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—SMO—bone cancer	3.41e-05	0.000707	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NT5C3A—bone cancer	3.41e-05	0.000707	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GRM4—bone cancer	3.3e-05	0.000683	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RGS1—bone cancer	3.3e-05	0.000683	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GRM1—bone cancer	3.29e-05	0.000682	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL3—bone cancer	3.26e-05	0.000675	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—GNA11—bone cancer	3.12e-05	0.000646	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL3—bone cancer	3.11e-05	0.000645	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.11e-05	0.000644	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.07e-05	0.000636	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.99e-05	0.00062	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NT5C3A—bone cancer	2.91e-05	0.000604	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GRM1—bone cancer	2.86e-05	0.000592	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL3—bone cancer	2.83e-05	0.000586	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NDUFA12—bone cancer	2.71e-05	0.000562	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.7e-05	0.000559	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PLAU—bone cancer	2.32e-05	0.000481	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SMO—bone cancer	2.32e-05	0.000481	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.25e-05	0.000466	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ENO2—bone cancer	2.17e-05	0.000449	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.12e-05	0.00044	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GNA11—bone cancer	2.12e-05	0.00044	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ENO2—bone cancer	2.12e-05	0.000439	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SMO—bone cancer	2.01e-05	0.000417	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—DHFR—bone cancer	2.01e-05	0.000417	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ATF1—bone cancer	1.97e-05	0.000409	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—DHFR—bone cancer	1.97e-05	0.000407	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL3—bone cancer	1.92e-05	0.000399	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GNA11—bone cancer	1.88e-05	0.000389	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GNA11—bone cancer	1.84e-05	0.000382	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GNA11—bone cancer	1.84e-05	0.000381	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ENO2—bone cancer	1.83e-05	0.000378	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.78e-05	0.000369	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ATF1—bone cancer	1.71e-05	0.000355	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP3A4—bone cancer	1.7e-05	0.000353	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—DHFR—bone cancer	1.69e-05	0.000351	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL3—bone cancer	1.67e-05	0.000346	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP3A4—bone cancer	1.67e-05	0.000345	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFBR2—bone cancer	1.65e-05	0.000341	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ENO2—bone cancer	1.64e-05	0.000339	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ENO2—bone cancer	1.6e-05	0.000331	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GNA11—bone cancer	1.58e-05	0.000328	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IGF1R—bone cancer	1.55e-05	0.000321	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—DHFR—bone cancer	1.52e-05	0.000315	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ENO2—bone cancer	1.51e-05	0.000312	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ENO2—bone cancer	1.49e-05	0.000309	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—DHFR—bone cancer	1.48e-05	0.000307	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTP1—bone cancer	1.46e-05	0.000302	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP3A4—bone cancer	1.43e-05	0.000297	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFBR2—bone cancer	1.43e-05	0.000296	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.43e-05	0.000296	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTP1—bone cancer	1.42e-05	0.000295	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GNA11—bone cancer	1.42e-05	0.000294	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—DHFR—bone cancer	1.4e-05	0.00029	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GNA11—bone cancer	1.39e-05	0.000287	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—DHFR—bone cancer	1.39e-05	0.000287	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF1R—bone cancer	1.34e-05	0.000279	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GNA11—bone cancer	1.31e-05	0.000271	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GNA11—bone cancer	1.3e-05	0.000268	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.29e-05	0.000267	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.28e-05	0.000265	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ENO2—bone cancer	1.28e-05	0.000264	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP3A4—bone cancer	1.26e-05	0.00026	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTP1—bone cancer	1.23e-05	0.000254	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.18e-05	0.000245	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—DHFR—bone cancer	1.18e-05	0.000245	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.17e-05	0.000243	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.17e-05	0.000242	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KIT—bone cancer	1.12e-05	0.000233	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GNA11—bone cancer	1.11e-05	0.000229	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTP1—bone cancer	1.1e-05	0.000228	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—bone cancer	1.08e-05	0.000223	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BRAF—bone cancer	1.06e-05	0.000219	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—bone cancer	1.02e-05	0.000212	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—bone cancer	1.01e-05	0.00021	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—bone cancer	1e-05	0.000208	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP3A4—bone cancer	1e-05	0.000208	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.98e-06	0.000207	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO2—bone cancer	9.85e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KIT—bone cancer	9.75e-06	0.000202	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—bone cancer	9.33e-06	0.000193	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—bone cancer	9.16e-06	0.00019	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—DHFR—bone cancer	9.14e-06	0.000189	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—bone cancer	8.88e-06	0.000184	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MDM2—bone cancer	8.84e-06	0.000183	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—bone cancer	8.58e-06	0.000178	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GNA11—bone cancer	8.54e-06	0.000177	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—bone cancer	7.69e-06	0.000159	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MDM2—bone cancer	7.68e-06	0.000159	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—bone cancer	7.55e-06	0.000156	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—bone cancer	7.48e-06	0.000155	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—bone cancer	7.38e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—bone cancer	6.67e-06	0.000138	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—bone cancer	6.62e-06	0.000137	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—bone cancer	6.49e-06	0.000135	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—bone cancer	6.36e-06	0.000132	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—bone cancer	6.04e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—bone cancer	5.71e-06	0.000118	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—bone cancer	5.57e-06	0.000115	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—bone cancer	5.25e-06	0.000109	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—bone cancer	5.25e-06	0.000109	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—bone cancer	5.2e-06	0.000108	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—bone cancer	5.07e-06	0.000105	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—bone cancer	4.45e-06	9.21e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—bone cancer	4.41e-06	9.13e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—bone cancer	3.43e-06	7.11e-05	CbGpPWpGaD
